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OBJECTIVES We sought to determine if elevated cardiac serum biomarkers after coronary artery bypass
graft surgery (CABG) are associated with increased medium-term mortality and to identify
patients that may benefit from better postoperative myocardial protection.
BACKGROUND The relationship between the magnitude of cardiac serum protein elevation and subsequent
mortality after CABG is not well defined, partly because of the lack of large, prospectively
studied patient cohorts in whom postoperative elevations of cardiac serum markers have been
correlated to medium- and long-term mortality.
METHODS The GUARD during Ischemia Against Necrosis (GUARDIAN) study enrolled 2,918
patients assigned to the entry category of CABG and considered as high risk for myocardial
necrosis. Creatine kinase-myocardial band (CK-MB) isoenzyme measurements were ob-
tained at baseline and at 8, 12, 16 and 24 h after CABG.
RESULTS The unadjusted six-month mortality rates were 3.4%, 5.8%, 7.8% and 20.2% for patients with
a postoperative peak CK-MB ratio (peak CK-MB value/upper limits of normal [ULN] for
laboratory test) of ,5, $5 to ,10, $10 to ,20 and $20 ULN, respectively (p , 0.0001).
The relationship remained statistically significant after adjustment for ejection fraction,
congestive heart failure, cerebrovascular disease, peripheral vascular disease, cardiac arrhyth-
mias and the method of cardioplegia delivery. Receiver operating characteristic curve analysis
revealed an area under the curve of 0.648 (p , 0.001); the optimal cut-point to predict
six-month mortality ranged from 5 to 10 ULN.
CONCLUSIONS Progressive elevation of the CK-MB ratio in clinically high-risk patients is associated with
significant elevations of medium-term mortality after CABG. Strategies to afford myocardial
protection both during CABG and in the postoperative phase may serve to improve the
clinical outcome. (J Am Coll Cardiol 2001;38:1070–7) © 2001 by the American College of
Cardiology
The relationship between the magnitude of creatine kinase-
myocardial band (CK-MB) isoenzyme elevation and subse-
quent mortality after coronary artery bypass graft surgery
(CABG) is not well defined because of the absence of large,
prospectively studied patient cohorts in whom post-
procedural elevations of CK-MB have been correlated to
medium- and long-term mortality (1–5). Most patients
have some degree of cardiac protein elevation after CABG
that can be detected using specific CK-MB bioassays (6). A
range of CK-MB 5 to 10 times the upper limits of normal
(ULN) is often used in clinical trials to identify a myocardial
infarction (MI) after CABG (1,7). However, there is sparse
data examining whether the magnitude of CK-MB eleva-
tion after CABG correlates with future mortality.
The recent joint European Society of Cardiology and
American College of Cardiology consensus document on
the re-definition of MI states that any degree of myocardial
necrosis caused by myocardial ischemia and detected using
cardiac serum markers after a revascularization intervention
should be labeled as an MI (8). The report recommends that
more data are needed to determine the magnitude of risk for
elevated cardiac serum markers after CABG.
The primary aim of this study was to determine whether
postoperative CK-MB elevation and electrocardiographic
(ECG) changes are associated with adverse six-month
mortality after CABG. The hypothesis was tested in 2,918
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patients entered into the CABG arm of the GUARD
during Ischemia Against Necrosis (GUARDIAN) study
(9,10).
METHODS
Study design. The GUARDIAN study was a multicenter,
multinational, double-blinded, placebo-controlled, random-
ized clinical trial that examined the efficacy of the Na1/H1
exchange inhibitor cariporide (HOE-642A) on the reduc-
tion of death or MI (9,10). Patient recruitment occurred
from May 1997 to August 1998. This study was approved
by the Institutional Review Board at each participating
institution, and written, informed consent was obtained
from all patients. The patients’ inclusion and exclusion
criteria are described elsewhere; patients at risk of myocar-
dial necrosis due to unstable angina or non–Q-wave MI
(n 5 5,233), high-risk percutaneous transluminal coronary
angioplasty (PTCA) (n 5 3,439) or high-risk CABG (n 5
2,918) were included (9). Patients were deemed to be at
high risk for CABG if they required an urgent intervention
(such as after failed PTCA) or repeat CABG, or if they had
a history of angina at rest or at minimal exercise within the
past four weeks and with the presence of two or more of the
following: age .65 years, female gender, diabetes mellitus,
left ventricular ejection fraction ,35% and left main or
three-vessel coronary artery disease. Patients with new ST
segment elevation MI, significant hepatic or renal impair-
ment or secondary causes of unstable angina, such as anemia
or hyperthyroidism, were excluded. The protocol specified
that all patients be contacted at six months to ascertain their
vital status, occurrence of MI and re-admission to the
hospital.
The patients’ demographic information, medical/surgical
history, 12-lead ECG and CK-MB enzyme levels were
collected at baseline, before CABG. The CK-MB enzyme
levels were also collected at 8, 12, 16 and 24 h after CABG.
Absolute units of CK-MB enzymes were graded on a
four-point scale (#60, .60 to #100, .100 to #200 and
.200 U/l). The peak CK-MB ratio was determined by
dividing the peak CK-MB value by the ULN for that
laboratory, because the ULN for CK-MB and type of assay
used varied across laboratories. Four categories were exam-
ined (,5, $5 to ,10, $10 to ,20 and $20 ULN).
Electrocardiograms obtained within 14 days postopera-
tively were considered for analysis. The ECGs were classi-
fied according to the Minnesota Code using an adaptation
of the Novacode system for serial Q-wave comparisons
(11,12). Serial ECG abnormalities from baseline were
coded as one- and two-step incremental changes of wors-
ening severity, as previously described (13).
Patient population. Of the 2,918 patients initially entered
into the CABG group of GUARDIAN, six-month vital
status was known for 2,891 (99.1%). Patients were excluded
if they died within 24 h of CABG (n 5 24), had MI at
study entry (preoperative CK-MB ratio . ULN) (n 5 96),
had no preoperative CK-MB enzyme determination (n 5
137) or had an insufficient number of postoperative
CK-MB values available to classify the event (n 5 111), or
if concomitant valve replacement surgery was performed
(n 5 129). Patients with concomitant valve surgery were
excluded because their six-month mortality rate was 17.8%
vs. 5.5% for patients without concomitant valve surgery, p ,
0.001), and their results represented only 4.4% of the total
group retained for analysis. The study population consisted
of the remaining 2,394 patients who underwent only
CABG, 131 of whom died during the six-month follow-up
period.
Statistical analysis. Differences in baseline demographic
data, medical/surgical histories and health characteristics
between patients who died during follow-up and those who
survived were assessed using the chi-square test for categor-
ical variables. The nonparametric Kolmogorov-Smirnov test
was used for all continuous variables (14). Odds ratios and
relative risks for six-month mortality were calculated for
CK-MB and ECG categories in relation to the baseline
level in that category (,5 ULN, #60 absolute units or ,2
steps of Minnesota Code worsening). Mortality was ex-
pressed per 100 patients (%). Cumulative six-month survival
by CK-MB categories was performed using life-table anal-
ysis according to 10-day increments after CABG (15). The
independent ability to predict six-month mortality using
demographic data, medical/surgical history, CK-MB en-
zyme levels and ECG variables was assessed by multiple
logistic regression analysis (16,17). Receiver operating char-
acteristic (ROC) curve analysis was performed to determine
the prognostic performance of different cut-points for the
CK-MB ratio to six-month mortality. All statistical analyses
were performed using SPSS, version 10.0 for Windows
(SPSS, Chicago, Illinois) and EPI Info, version 6.04b
(CDCP, Atlanta, Georgia).
RESULTS
Demographic data and medical/surgical history (Table
1). Patients who died during the six-month follow-up had
a lower baseline ejection fraction and were more likely to
have had a history of MI, congestive heart failure, cerebro-
Abbreviations and Acronyms
AUC 5 area under the curve
CABG 5 coronary artery bypass graft surgery
CK-MB 5 creatine kinase-myocardial band
ECG 5 electrocardiogram or
electrocardiographic
GUARDIAN 5 GUARD during Ischemia Against
Necrosis
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
ROC 5 receiver operating characteristic
ULN 5 upper limits of normal
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vascular disease, peripheral vascular disease, cardiac arrhyth-
mias and insulin-dependent diabetes mellitus, compared
with patients who survived. Retrograde cardioplegia delivery
was less likely to be associated with six-month mortality.
Intermittent cross-clamping was more likely to be associ-
ated with six-month mortality. Most patients received a
cold cardioplegic solution. The number and type of graft(s)
inserted, the use of blood versus crystalloid solution and the
temperature of the cardioplegic solution were not signifi-
cantly different between survivors and nonsurvivors.
Relationship between peak CK-MB enzyme levels and
six-month mortality (Tables 2 and 3). Increasing peak
CK-MB enzyme ratios were associated with a greater risk of
death (Table 2). The six-month mortality rates for patients
with peak CK-MB ratios of ,5, $5 to ,10, $10 to ,20
and $20 ULN were 3.4%, 5.8%, 7.8% and 20.2%, respec-
tively (p , 0.0001). The test for trend was significant
(chi-square 5 70.52 at 1 df, p , 0.0001). The converse is
shown in Figure 1, where cumulative six-month survival was
inversely related to the peak CK-MB ratio (p , 0.0001).




Follow-Up (n 5 131)
Patients Who
Survived 6-Month
Follow-Up (n 5 2263) p Value
Age (yr) 68.0 68.0 0.30
Gender
Male 86 (65.6%) 1,582 (69.9%) 0.35
Female 45 (34.4%) 681 (30.1%)
Race*
White 122 (93.1%) 2,129 (94.1%)
Black 6 (4.6%) 89 (3.9%) 0.90
Asian 2 (1.5%) 22 (1.0%)
Multiracial 1 (0.8%) 22 (1.0%)
BMI† (kg/m2) 27.2 27.6 0.64
Ejection fraction‡
,35% 36 (39.6%) 245 (16.0%) ,0.0001
$35% 55 (60.4%) 1,289 (84.0%)
Myocardial infarction 90 (68.7%) 1,241 (54.8%) ,0.01
Congestive heart failure 43 (32.8%) 332 (14.7%) ,0.0001
Cerebrovascular disease 35 (26.7%) 328 (14.5%) ,0.0001
Peripheral vascular disease 42 (32.1%) 376 (16.6%) ,0.0001
Cardiac arrhythmias 48 (36.6%) 447 (19.8%) ,0.0001
Insulin-dependent diabetes mellitus 25 (19.1%) 263 (11.6%) ,0.05
Non–insulin-dependent diabetes mellitus 36 (27.5%) 651 (28.8%) 0.83
Diabetes, type not specified 4 (3.1%) 27 (1.2%) 0.15
Previous PTCA 48 (36.6%) 1,018 (45.0%) 0.16
Previous CABG 50 (38.2%) 928 (41.0%) 0.58
Method of cardioplegia delivery
(not mutually exclusive)
Anterograde 104 (84.6%) 1,944 (89.0%) 0.17
Retrograde 38 (30.9%) 984 (45.0%) ,0.01
Intermittent cross-clamp 32 (26.0%) 330 (15.1%) ,0.01
Type of cardioplegic solution
(not mutually exclusive)
Blood 86 (72.3%) 1,465 (68.4%) 0.43
Crystalloid 55 (46.2%) 1,160 (54.2%) 0.11
Other 11 (9.2%) 152 (7.1%) 0.48
Cardioplegia solution temperature
(not mutually exclusive)
Cold 100 (87.0%) 1,956 (91.7%) 0.11
Warm 34 (29.6%) 571 (26.8%) 0.58
Duration of cardiopulmonary bypass (min) 105 94 ,0.001
Total surgical time (min) 295 266 ,0.001
Peak CK-MB values (U/l) 36.0 17.5 ,0.0001
Peak CK-MB ratio 7.2 3.5 ,0.0001
Duration of follow-up (days) 22.0 191.0 ,0.0001
*Race was unknown for one patient who survived; †body mass index (BMI) was unknown for three patients who survived;
‡ejection fraction was unknown for 40 patients who died and for 729 patients who survived. Data are presented as the median
value or number (%) of patients.
CABG 5 coronary artery bypass graft surgery; CK-MB 5 creatine kinase-myocardial band isoenzymes; PTCA 5
percutaneous transluminal coronary angioplasty.
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Similar results were obtained when the patients were strat-
ified by peak CK-MB enzyme values (p , 0.0001) (Table 3,
Fig. 2). The area under the curve (AUC) on ROC analysis
was 0.648 (p , 0.0001) (Fig. 3). The sensitivity and
specificity for using various cut-points of peak CK-MB
enzyme ratios to correctly identify patients who did and did
not die during the six-month follow-up period indicate that
the optimal cut-point for prognostic performance lies be-
tween 5 and 10 ULN. The sensitivity and specificity for the
5-, 10-, 15- and 20-ULN cut-points were 0.60 and 0.66,
0.39 and 0.85, 0.29 and 0.91 and 0.26 and 0.94, respec-
tively.
Relationship between ECG abnormalities and six-month
mortality (Table 4). The presence of new Q-wave wors-
ening of two grades, according to the Minnesota Code, was
significantly associated with six-month mortality. One hun-
dred and ten patients developed new Q-wave worsening of
two grades (Minnesota Code) after CABG. The six-month
mortality rate was 10.9% in these 110 patients, compared
with 4.8% in the 2,222 patients without new postoperative
Q-waves (p , 0.01). Thirty-eight of the 110 patients had
peak CK-MB ratios ,5 ULN, and 72 had peak CK-MB
ratios $5 ULN. The six-month mortality rates were 2.6%
and 15.3%, respectively (p 5 0.09). The six-month mortal-
ity rates for the 2,222 patients who did not develop a new
Q-wave worsening of two grades (Minnesota Code) were
3.1% for patients whose peak CK-MB ratio was ,5 ULN
and 8.0% for patients whose peak CK-MB ratio was $5
ULN (p , 0.0001).
Multivariate modeling for six-month mortality risk (Ta-
bles 5 and 6). The independent ability to predict six-
month mortality using all significant univariate variables was
examined through multiple logistic regression analysis. The
results of the final model are presented. The strongest
predictor of six-month mortality was the peak CK-MB
enzyme ratio. When the model was run as a binary variable
($5 vs. ,5 ULN), two-grade Q-wave worsening (Minne-
sota Code) was a significant independent predictor of
six-month mortality (odds ratio 1.99, p , 0.05). Two
models were run to adjust for the 751 patients with missing
ejection fraction measurements. The first model imputed
the mean ejection fraction for all patients with missing
values; the second model used a category of “missing” for
patients with a missing ejection fraction. The models gave
virtually identical results. The findings were similar when
peak CK-MB value categories, rather than peak CK-MB
ratio categories, were tested in the model.
Of the 131 patients who died during the six-month
follow-up period after CABG, 43 occurred within 10 days
of the operation. To examine the impact of these early
deaths on the relationship between the peak CK-MB ratio
and six-month mortality, the analyses were repeated using
only patients that survived .10 days after CABG (Table 6).
A history of cerebrovascular disease was no longer predictive
of six-month mortality; previous PTCA and the number of
bypass grafts were new variables that were predictive of
decreased six-month mortality. The peak CK-MB ratio
remained a significant predictor of six-month mortality in
the final multiple logistic regression model, indicating that
this finding is representative of the survival experience
throughout the duration of the follow-up phase.
DISCUSSION
This report demonstrates that a large, prospectively studied,
clinically high-risk patient population undergoing CABG
in 1997 to 1998 has an increasing risk of six-month
mortality, with increasing levels of postoperative CK-MB
elevation. The risk gradient remained significant after ad-
justment for ejection fraction, congestive heart failure,

















,5 ULN 52 1,474 1,526 0.035 1.00* 3.41 1.00*
$5 and ,10 ULN 27 441 468 0.061 1.74† 1.05–2.86 5.77 1.69† 1.08–2.66
$10 and ,20 ULN 18 214 232 0.084 2.38‡ 1.32–4.28 7.76 2.28‡ 1.36–3.82
$20 ULN 34 134 168 0.254 7.19§ 4.39–11.76 20.24 5.94§ 3.97–8.88
Total 131 2,263 2,394 0.058 5.47
*Reference category; †p , 0.05; ‡p , 0.01; §p , 0.00001.
CI 5 confidence interval; CK-MB 5 creatine kinase-myocardial band; ULN 5 upper limits of normal.

















#60 U/l 78 1,920 1,998 0.041 1.00* 3.90 1.00*
.60 and #100 U/l 11 161 172 0.068 1.68 0.83–3.34 6.40 1.64 0.89–3.02
.100 and #200 U/l 22 129 151 0.171 4.20† 2.45–7.14 14.57 3.73† 2.40–5.81
.200 U/l 20 53 73 0.377 9.29† 5.09–16.84 27.40 7.02† 4.56–10.81
Total 131 2,263 2,394 0.058 5.47
*Reference category; †p , 0.00001.
Abbreviations as in Table 2.
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cerebrovascular disease, peripheral vascular disease, cardiac
arrhythmias and the method of cardioplegia delivery.
The study population in this report consisted of 2,918
patients who were initially entered into the CABG arm of
the GUARDIAN study (9,10). The data set is unique in
several aspects. The study cohort contained a large number
of patients receiving isolated CABG procedures, allowing
for a robust analysis of the mortality end point. Cardiac
enzyme values were prospectively collected as part of the
study protocol, thus avoiding sampling bias. Six-month
follow-up was vigorously pursued for the mortality end
point, with ,1% of patients lost to follow-up. The patients
received CABG in the modern era (1997–98) and in a
multicenter trial, thus increasing the generalizability of the
results. The six-month mortality gradient was observed with
increasing levels of peak CK-MB enzyme ratios or with
peak absolute units of CK-MB enzymes. The consistency of
the data—that is, the strong dose-response relationship
between the magnitude of postoperative CK-MB elevation
and six-month mortality and the results of multivariate
model analysis—strongly argues against these findings being
the result of chance. Our data indicate that the relationship
between the CK-MB ratio and six-month mortality cannot
be entirely attributed to patients who die within the
hospital shortly after the operation, because the relation-
ship between the CK-MB ratio and six-month mortality
remained significant, even after early deaths (,11 days)
were excluded. The likelihood that the elevated postop-
erative CK-MB values represent myocardial necrosis in
most patients is supported by the findings of Force et al.
Figure 1. Cumulative six-month survival rates according to the peak creatine kinase-myocardial band ratio category (p , 0.0001). All pairwise comparisons
between the categories were significant, except for the $5 and ,10 upper limits of normal (ULN) group versus the $10 and ,20 ULN group (p 5 0.26).
CABG 5 coronary artery bypass graft surgery.
Figure 2. Cumulative six-month survival rates according to the peak creatine kinase-myocardial band value category (p , 0.0001). All pairwise comparisons
between the categories were significant, except for the #60 U/l group versus the .60 and #100 U/l group (p 5 0.09). CABG 5 coronary artery bypass
graft surgery.
1074 Klatte et al. JACC Vol. 38, No. 4, 2001
CK-MB Ratio After CABG October 2001:1070–7
(18), who report an increased frequency of new postop-
erative regional wall motion abnormalities on two-
dimensional echocardiograms, with increasing levels of
CK-MB.
Optimal CK-MB ratio cut-point to define MI. Death
and MI are a common composite end point used to
determine the sample size for clinical trials. Larger MIs, as
defined by CK-MB .10 ULN, are a “bad” outcome, and
prevention of this magnitude of damage is a desired treat-
ment outcome. Thus, CK-MB elevation $10 ULN or
.100 U/l within 24 h after CABG constitutes a robust
definition of peri-procedural MI that could be used as part
of a composite clinical end point of death or MI in studies
testing the efficacy of new cardioprotective compounds. The
decision to use peak CK-MB enzyme ratios $5 or $10
ULN to define peri-procedural MI in the setting of clinical
studies of CABG depends on the question being addressed
(19–21). A more sensitive definition may be desirable to
satisfy sample-size requirements in the proof-of-concept
phase. The lower cut-point of the peak CK-MB ratio of $5
would result in a greater number of end point events (;11⁄2
times as many for $10 ULN). A more stringent and specific
definition of a peak CK-MB ratio $10 ULN, however, may
be preferred to confirm clinical efficacy. The use of a lower
cut-point increases the risk of confounding the MI end
point variable by including patients with nonischemic,
surgically induced myocardial injury. This would affect the
specificity of the definition with respect to the medium-
term clinical outcome.
Electrocardiographic findings. Development of a new
Q-wave worsening of two grades, according to the Minne-
sota Code, after CABG was a statistically significant uni-
variate predictor of six-month mortality. After adjustment
for baseline variables and postoperative peak CK-MB ratios,
however, the risk was attenuated. The adverse long-term
(i.e., five years) outcome for patients who develop this new
two-grade Q-wave worsening has been well demonstrated
in the Coronary Artery Surgery Study and the Bypass
Angioplasty Revascularization Investigation (22–24). Major
Q-wave items have been observed after CABG by unmask-
ing a previous MI in a small number of patients (25). In
GUARDIAN, the relative six-month mortality risk for new
postoperative Q-waves was not increased when the peak
CK-MB ratio was ,5 ULN. Thus, the likelihood of
peri-operative myocardial necrosis is greatest when new
postoperative Q-waves are accompanied by abnormally
elevated cardiac serum biomarkers, such as CK-MB. Alter-
natively, in this particular patient subset with a lower peak
CK-MB ratio, the prognostic significance of postoperative
Figure 3. Receiver operating characteristic curve predicting six-month mortality at various levels of peak creatine kinase-myocardial band (CK-MB) enzyme
ratios. ULN 5 upper limits of normal.



















None or one step 54.4 74 1,194 1,268 0.062 1.00* 5.84 1.00*
2-step worsening T-wave 23.6 18 532 550 0.034 0.55† 0.31–0.95 3.27 0.56† 0.34–0.93
2-step worsening ST segment elevation 14.2 11 320 331 0.034 0.55 0.27–1.09 3.32 0.57 0.31–1.06
2-step worsening ST segment depression 2.7 4 59 63 0.068 1.09 0.33–3.24 6.35 1.09 0.41–2.88
2-step worsening ST segment elevation and
2-step worsening ST segment depression
0.4 0 10 10 0.000 0.00 — 0.00 0.00 —
2-step worsening Q-wave 4.7 12 98 110 0.122 1.98 0.98–3.90 10.91 1.87† 1.05–3.33
*Reference category; †p , 0.05.
ECG 5 electrocardiographic; CI 5 confidence interval.
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Q-waves may require a longer term follow-up to determine
their importance.
Operative characteristics. The use of blood or crystalloid
cardioplegia had no effect on survival. There was a favorable
association between retrograde cardioplegia and a reduction
of six-month mortality. Intermittent cross-clamping was
associated with an increased six-month mortality rate. The
duration of cardiopulmonary bypass and total surgical time
did not significantly predict six-month mortality after ad-
justment for the peak CK-MB ratio and other co-variates.
Study limitations. The interpretation of our data may be
complicated by several potential limitations. The patients
enrolled in GUARDIAN comprised a clinical patient subset
at increased risk of peri-procedural myocardial necrosis, and
it is unclear whether the observed relationship can be
extrapolated to patients who are at lower clinical risk at the
time of the operation. Although baseline variables known to
impact mortality were controlled for in the multivariate
models, the analysis may not have included complete
consideration of all of the important coronary morphologic
characteristics on the angiogram or all of the procedural
variables that may have had an impact on prognosis. The
number of CK-MB samples obtained did not allow for
calculation of the AUC for CK-MB release. Nevertheless,
the increased mortality risk associated with elevated
CK-MB enzymes postoperatively indicates that these pa-
tients most likely have had a postoperative MI and should
be considered for drug therapy, such as beta-blockers and
angiotensin-converting enzyme inhibitors, to decrease the
postoperative risk of death (26,27). More research is needed
in this area to determine whether cardioactive drugs that
have been shown to be beneficial in medically treated
post-infarction patients reduce mortality in postoperative
patients with elevated CK-MB values. The highest caripo-
ride dose investigated in the GUARDIAN trial reduced the
mean CK-MB ratio elevation. This reduction was associ-
ated not only with a lowering of the primary composite end
point of death or MI manifested early during the treatment
phase, but also with the long-term secondary end point of
events related to left ventricular dysfunction. Death rates,
however, were unaffected at any time point (10). Cardiac
troponin I measurements were available in only a small
number of GUARDIAN patients (n 5 176). The use of
cardiac troponin measurements to predict outcome after
CABG is an area of active research, although there are
currently no data from large-scale clinical trials to correlate
the magnitude of troponin release to medium- or long-term
clinical outcomes (3,28–30). Our data apply to patients who
have undergone cardiopulmonary bypass and cardioplegic ar-
rest. The results have not been tested in patients who have
off-pump surgery. Cardiac serum marker release after off-pump
surgery is generally lower than that after on-pump surgery (31).
Conclusions. Our findings support the routine collection
of CK-MB enzyme levels after clinically high-risk CABG,
not only for diagnostic purposes, but also for prognostic
guidance and treatment that may potentially reduce the high
six-month mortality rates seen in patients with larger
amounts of CK-MB enzyme release.
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Six-Month Mortality in Patients Who Survived .10 Days
After CABG
Odds




Congestive heart failure 2.15 1.23–3.76 ,0.01
Peripheral vascular disease 2.23 1.33–3.73 ,0.01
Cardiac arrhythmias 2.38 1.44–3.93 ,0.001
Previous PTCA 0.60 0.36–1.00 ,0.05
Retrograde cardioplegia 0.32 0.18–0.56 ,0.001
No. of arterial bypass grafts 0.64 0.45–0.91 ,0.05
Peak CK-MB isoenzyme ratio
,5 ULN 1.00
$5 and ,10 ULN 1.90 1.04–3.48 ,0.05
$10 and ,20 ULN 1.97 0.94–4.14 0.08
$20 ULN 4.78 2.37–9.64 ,0.001
Abbreviations as in Tables 1 and 2.
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